NET Tumor of the EG Junction

Home Forums Edits Vendor and Central Registry Metafile Administrators NET Tumor of the EG Junction

Viewing 1 post (of 1 total)
  • Author
  • #3278

    Per the official response on the CAnswer Forum, a site histology combination of EGJunction and neuroendocrine carcinoma is unstageable for AJCC 7. Based on Site Histology combinations of C160 and 8246/3, the primary can be staged with the NET Chapter and Schema. If the response is indeed correct, it will need to be addressed beyond edits, as the schema discriminator will need to be required for NET tumors. This will also affect software DLLs.

    A quick query and manual review shows very low frequency of this exact situation. A more thorough analysis could be done upon request if needed.

Viewing 1 post (of 1 total)
  • The forum ‘Vendor and Central Registry Metafile Administrators’ is closed to new topics and replies.

Copyright © 2018 NAACCR, Inc. All Rights Reserved | naaccr-swoosh-only See NAACCR Partners and Sponsors